SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001764013-21-000003
Filing Date
2021-01-14
Accepted
2021-01-14 09:03:45
Documents
3
Period of Report
2021-01-11

Document Format Files

Seq Description Document Type Size
1 FORM 3 wf-form3_161063300831262.html 3  
1 FORM 3 wf-form3_161063300831262.xml 3 1707
2 POWER OF ATTORNEY RITA V2 a4immunovantinc-powerofa.htm EX-24 4685
3 POWER OF ATTORNEY RITA V2 a4immunovantinc-powerofa001.jpg GRAPHIC 267014
  Complete submission text file 0001764013-21-000003.txt   375757
Mailing Address C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET, SUITE 1100 CAMBRIDGE MA 02142
Business Address
Jain Rita (Reporting) CIK: 0001707797 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38906 | Film No.: 21527586

Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Issuer) CIK: 0001764013 (see all company filings)

IRS No.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
SIC: 2836 Biological Products, (No Diagnostic Substances)